Last reviewed · How we verify
Tritanrix-HepB/Hib™ + OPV vaccine
Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.
Tritanrix-HepB/Hib™ + OPV vaccine works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus.
At a glance
| Generic name | Tritanrix-HepB/Hib™ + OPV vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated or weakened forms of these pathogens, which are introduced to the body to trigger an immune response. The immune system then produces antibodies to fight these pathogens, providing immunity against future infections.
Approved indications
- Protection against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliovirus
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Fatigue
Key clinical trials
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine (PHASE3)
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age. (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)
- Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants (PHASE3)
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. (PHASE3)
- Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine (PHASE3)
- Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix-HepB/Hib™ + OPV vaccine CI brief — competitive landscape report
- Tritanrix-HepB/Hib™ + OPV vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI